Difference between revisions of "YvrHb"
| Line 1: | Line 1: | ||
| − | * '''Description:''' | + | * '''Description:''' two-component response regulator <br/><br/> |
{| align="right" border="1" cellpadding="2" | {| align="right" border="1" cellpadding="2" | ||
| Line 8: | Line 8: | ||
|style="background:#ABCDEF;" align="center"| '''Synonyms''' || '' '' | |style="background:#ABCDEF;" align="center"| '''Synonyms''' || '' '' | ||
|- | |- | ||
| − | |style="background:#ABCDEF;" align="center"| '''Essential''' || | + | |style="background:#ABCDEF;" align="center"| '''Essential''' || no |
|- | |- | ||
| − | |style="background:#ABCDEF;" align="center"| '''Product''' || | + | |style="background:#ABCDEF;" align="center"| '''Product''' || two-component response regulator |
|- | |- | ||
|style="background:#ABCDEF;" align="center"|'''Function''' || write here | |style="background:#ABCDEF;" align="center"|'''Function''' || write here | ||
| Line 38: | Line 38: | ||
===Phenotypes of a mutant === | ===Phenotypes of a mutant === | ||
| + | |||
| + | unusual autolysis and higher susceptibility to cell envelope antibiotics (bacitracin, aztreonam, cefepime, fosfomycin) [http://www.ncbi.nlm.nih.gov/sites/entrez/16306698 PubMed] | ||
=== Database entries === | === Database entries === | ||
| Line 47: | Line 49: | ||
=== Additional information=== | === Additional information=== | ||
| − | |||
=The protein= | =The protein= | ||
| Line 53: | Line 54: | ||
=== Basic information/ Evolution === | === Basic information/ Evolution === | ||
| − | * '''Catalyzed reaction/ biological activity:''' | + | * '''Catalyzed reaction/ biological activity:''' transcription activator [http://www.ncbi.nlm.nih.gov/sites/entrez/16306698 PubMed] |
| + | |||
| + | * '''Protein family:''' OmpR family | ||
| + | |||
| + | * '''Paralogous protein(s):''' | ||
| + | |||
| + | === The YvrHb regulon === | ||
| − | + | subject to positive control: ''[[dltA]]-[[dltB]]-[[dltC]]-[[dltD]]-[[dltE]], [[sigX]]-[[rsiX]], [[sunA]], [[sunT]]-[[bdbA]]-[[yolJ]]-[[bdbB]], [[wapA]]-[[yxxG]], [[wprA]], [[yvrI]]-[[yvrHa]]'' [http://www.ncbi.nlm.nih.gov/sites/entrez/16306698 PubMed] | |
| − | + | subject to negative control: ''[[lytA]]-[[lytB]]-[[lytC]]'' [http://www.ncbi.nlm.nih.gov/sites/entrez/16306698 PubMed] | |
=== Extended information on the protein === | === Extended information on the protein === | ||
| Line 63: | Line 70: | ||
* '''Kinetic information:''' | * '''Kinetic information:''' | ||
| − | * '''Domains:''' | + | * '''Domains:''' |
| − | * '''Modification:''' | + | * '''Modification:''' phosphorylation (Asp) by [[YvrG]] [http://www.ncbi.nlm.nih.gov/sites/entrez/16306698 PubMed] |
* '''Cofactor(s):''' | * '''Cofactor(s):''' | ||
| Line 71: | Line 78: | ||
* '''Effectors of protein activity:''' | * '''Effectors of protein activity:''' | ||
| − | * '''Interactions:''' | + | * '''Interactions:''' YvrG-[[YvrHb]] [http://www.ncbi.nlm.nih.gov/sites/entrez/16306698 PubMed] |
* '''Localization:''' | * '''Localization:''' | ||
| Line 104: | Line 111: | ||
* '''Expression vector:''' | * '''Expression vector:''' | ||
| − | + | ||
* '''lacZ fusion:''' | * '''lacZ fusion:''' | ||
| Line 119: | Line 126: | ||
=References= | =References= | ||
| + | # Serizawa M, Kodama K, Yamamoto H, Kobayashi K, Ogasawara N, Sekiguchi J. (2005) Functional analysis of the YvrGHb two-component system of ''Bacillus subtilis'': identification of the regulated genes by DNA microarray and northern blot analyses. ''Biosci. Biotechnol. Biochem.'' '''69:''' 2155-2169. [http://www.ncbi.nlm.nih.gov/sites/entrez/16306698 PubMed] | ||
# Author1, Author2 & Author3 (year) Title ''Journal'' '''volume:''' page-page. [http://www.ncbi.nlm.nih.gov/sites/entrez/PMID PubMed] | # Author1, Author2 & Author3 (year) Title ''Journal'' '''volume:''' page-page. [http://www.ncbi.nlm.nih.gov/sites/entrez/PMID PubMed] | ||
Revision as of 19:14, 4 March 2009
- Description: two-component response regulator
| Gene name | yvrHb |
| Synonyms | |
| Essential | no |
| Product | two-component response regulator |
| Function | write here |
| MW, pI | xx,x kDa, y.yy |
| Gene length, protein length | aaa bp, bbb amino acids |
| Immediate neighbours | yvrHa, yvrG |
| Gene sequence (+200bp) | Protein sequence |
Genetic context 
| |
Contents
The gene
Basic information
- Coordinates (CDS):
Phenotypes of a mutant
unusual autolysis and higher susceptibility to cell envelope antibiotics (bacitracin, aztreonam, cefepime, fosfomycin) PubMed
Database entries
- DBTBS entry: no entry
- SubtiList entry: no entry
Additional information
The protein
Basic information/ Evolution
- Catalyzed reaction/ biological activity: transcription activator PubMed
- Protein family: OmpR family
- Paralogous protein(s):
The YvrHb regulon
subject to positive control: dltA-dltB-dltC-dltD-dltE, sigX-rsiX, sunA, sunT-bdbA-yolJ-bdbB, wapA-yxxG, wprA, yvrI-yvrHa PubMed
subject to negative control: lytA-lytB-lytC PubMed
Extended information on the protein
- Kinetic information:
- Domains:
- Cofactor(s):
- Effectors of protein activity:
- Localization:
Database entries
- Structure:
- Swiss prot entry:
- KEGG entry:
- E.C. number:
Additional information
Expression and regulation
- Operon:
- Sigma factor:
- Regulation:
- Regulatory mechanism:
- Additional information:
Biological materials
- Mutant:
- Expression vector:
- lacZ fusion:
- GFP fusion:
- two-hybrid system:
- Antibody:
Labs working on this gene/protein
Your additional remarks
References
- Serizawa M, Kodama K, Yamamoto H, Kobayashi K, Ogasawara N, Sekiguchi J. (2005) Functional analysis of the YvrGHb two-component system of Bacillus subtilis: identification of the regulated genes by DNA microarray and northern blot analyses. Biosci. Biotechnol. Biochem. 69: 2155-2169. PubMed
- Author1, Author2 & Author3 (year) Title Journal volume: page-page. PubMed
